A combination of sacituzumab govitecan and pembrolizumab showed a “high response rate” in patients with advanced urothelial carcinoma previously treated with platinum-based chemotherapy. In the TROPHY-U-01 trial cohort, 41 patients were treated with the combination, and a 41% objective response rate was observed. The median duration of response was 11.1 months, median progression-free survival was 5.3 months, and median overall survival was 12.7 months. Treatment-related adverse events were observed in all patients, with grade 3 or higher events occurring in 61% of patients. The researchers concluded that the combination supports further evaluation in advanced urothelial carcinoma. This research was supported by Gilead Sciences, Inc.
Source link
Sacituzumab Govitecan Plus Pembrolizumab Proves Active in Advanced Urothelial Carcinoma
